Addressing Critical Challenges in Systemic Disease Detection and Escalating Eye Health Issues
The first problem is that the detection of systemic disease is expensive and inefficient requiring the patient to access specialty centers and approvals… and cannot be done at home. Downfalls:
1. NIH PubMed; Estimated number of ophthalmologists worldwide (International Council of Ophthalmology update): will we meet the needs?
2. The International Agency for the Prevention of Blindness (IAPB); Mapping the global optometry workforce July 20, 2021.
“It's imperative that we make vision care accessible, affordable, available, and easy to use for both patients and practitioners.”
– Dr. Jerry Katzman, MD
There is an inefficient, limited, and costly use of eyecare specialists.
1.Pitchbook; Healthcare Services Report Nov. 7, 2023.
2. AMA-ASSN Doctor shortages are here—and they’ll get worse if we don’t act fast. Apr. 2022.
3. Statista; Americans without health insurance – statistics & facts. Aug. 2023.
4. WHO; Universal Health Coverage Fact Sheet. Oct. 2023.
Realizing improvements in drug validation, efficacy, effectiveness and safety is an unending global challenge. Drug development, from initial discovery of a promising target to the final medication, is an expensive, lengthy and incremental process. New drugs are important to address new diseases, the development of drug resistance, and our increasing understanding of health conditions allowing treatment of previously untreatable conditions. In some cases, it may not be a new drug that is required, but that a previously known drug can be used for a new purpose. Fresh solutions are needed to meet these challenges.